Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 7/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.33 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.33 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.33 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14642530 | 0.92 | ACVRL1 (0.36) | ACVRL1RIPK1CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL14642542 | 0.88 | CSNK2A2 (0.36) | ACVRL1RIPK1CSNK2A2CSNK2A1AXL | |
| SCHEMBL14642599 | 0.84 | ACVRL1 (0.37) | ACVRL1PIK3CD | |
| SCHEMBL14642596 | 0.81 | PIK3CD (0.41) | ACVRL1PIK3CD | |
| SCHEMBL10105828 | 0.80 | ACVRL1 (0.39) | ACVRL1CSNK2A2CSNK2A1AXLMERTK | |
| SCHEMBL13519789 | 0.80 | LGALS3 (0.35) | ACVRL1 | |
| SCHEMBL14642529 | 0.80 | PIK3CD (0.37) | ACVRL1CSNK2A2CSNK2A1AXLMERTK | |
| SCHEMBL10101576 | 0.79 | CSNK2A2 (0.34) | ACVRL1CSNK2A2CSNK2A1AXLMERTK | |
| SCHEMBL10101513 | 0.79 | CSNK2A2 (0.34) | ACVRL1CSNK2A2CSNK2A1AXLMERTK | |
| SCHEMBL10100350 | 0.78 | HIF1A (0.41) | ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-17 | — | — | US | disclosed |
| WO-2010002877-A2 | BYCYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | ACVRL1 4215/4885RIPK1 3382/4885CSNK2A2 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.